Ophthalmology

The Worldwide Medical Laser System Industry is Expected to Witness a CAGR of 12.85% to 2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Medical Supplies, Medical Devices, Urology, Awareness, Dermatology, Ophthalmology, Dentistry, Growth, Patient, Cardiology, Investment, CAGR, Government, Adoption, Health insurance

Increase in cases of eye disorder is a key driver for the growth of the global medical laser system market.

Key Points: 
  • Increase in cases of eye disorder is a key driver for the growth of the global medical laser system market.
  • Nevertheless, side effects related with the laser treatment and strict governing situation in the developed economies are expected to restrain the global market growth.
  • Based on product, the market is categorized into gas laser, diode laser, solid state lasers, and dye lasers.
  • In 2021, the diode laser segment accounted for the substantial revenue share with lucrative CAGR during the forecast period.

AGTC to Present at Upcoming American Society of Retina Specialists Annual Meeting

Retrieved on: 
Thursday, July 7, 2022
Assistant, Nyctalopia, Patient, Color, Achromatopsia, RPGR, Control, ASRS, Trial of the century, Retina, GLOBE, Man, COVID-19, AAV, CNS, Disease, Central nervous system, Annual report, Eye, Neurotology, Constriction, CNGB3, ACHM, Optogenetics, Therapy, Technology, Visual acuity, Nasdaq, SEC, Applied Genetic Technologies Corporation, Form 10-K, Drug development, Severe cognitive impairment, Safety, Central nervous system disease, Society, MD, Retinitis pigmentosa, Forward-looking statement, Pharmaceutical industry, Adult, Ophthalmology

Each presentation will be shared during the American Society of Retina Specialists (ASRS) Annual Meeting, taking place July 13-16 in New York City.

Key Points: 
  • Each presentation will be shared during the American Society of Retina Specialists (ASRS) Annual Meeting, taking place July 13-16 in New York City.
  • We are honored to join our colleagues in the ophthalmology community, during this important retina meeting, to present data from the exciting gene therapies we are developing at AGTC as potential treatments for both ACHM and XLRP, said Dr. Susan Schneider, Chief Medical Officer of AGTC.
  • We look forward to sharing future updates as we continue to progress these assets through their respective clinical development paths.
  • Also, forward-looking statements represent managements plans, estimates, assumptions and beliefs only as of the date of this release.

QHP Capital Acquires Lexitas Pharma Services

Retrieved on: 
Thursday, July 7, 2022
Professional Services, Health, Finance, Pharmaceutical, Optical, Biotechnology, Efficiency, Retinitis pigmentosa, Acquisition, Science, Patient, CEO, Ophthalmology, Lists of people executed in the United States, Growth, Company, Industry, Goal, Diversified Pharmaceutical Services, Partner, CRO, Glaucoma, QHP, Duane syndrome, Clinical trial, Technology, Cataract, Board, Diabetic retinopathy, Vance DeGeneres, Drug development, Uveitis, Fine chemical, Pharmaceutical industry

QHP Capital (QHP), the management company for NovaQuest Private Equity (NQPE), today announced its acquisition of Lexitas Pharma Services (Lexitas or the Company), a full-service ophthalmology contract research organization (CRO) supporting biopharmaceutical and medical device clinical trials.

Key Points: 
  • QHP Capital (QHP), the management company for NovaQuest Private Equity (NQPE), today announced its acquisition of Lexitas Pharma Services (Lexitas or the Company), a full-service ophthalmology contract research organization (CRO) supporting biopharmaceutical and medical device clinical trials.
  • Lexitas is an excellent fit with QHPs philosophy and strategy of providing strategic capital to growing clinical trial services providers in niche, specialized therapeutic areas, said Vern Davenport and Jeff Edwards, Partners at QHP.
  • We look forward to supporting the Lexitas team as they continue to build out their capabilities and provide best-in-class ophthalmic drug development services.
  • QHP Capital, L.P. (the Firm), is the management company for NovaQuest Private Equity (NQPE).

Global Ophthalmology Market Report 2022: Featuring Key Players Johnson & Johnson Vision, ClearSight, PanOptica & Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, Optical, Allergic conjunctivitis, Decision-making, Acquisition, USD, Howard Hughes Medical Institute, Strategic management, Market share analysis, Inflammation, Value, Business Growth Fund, Mergers and acquisitions, Customer support, Growth, Ophthalmology, Research report, Collaborative partnership, Gaps, Contract research organization, Investment, Equipment, CAGR, Weakness, Lens (anatomy), Use, Health, News, Compound annual growth rate, State, Retail, Cataract, Glaucoma, Hospital, Drug, Software

Based on Product Type, the market was studied across Drugs, Equipment, Prescription Glasses & Lens, and Software.

Key Points: 
  • Based on Product Type, the market was studied across Drugs, Equipment, Prescription Glasses & Lens, and Software.
  • The Drugs is further studied across Allergic Conjunctivitis & Inflammation Drugs, Dry Eye Drugs, Glaucoma Drugs, and Retinal Disorder Drugs.
  • Based on End User, the market was studied across Healthcare Service Providers, Hospitals, Medical Institutes, and Research Organizations.
  • The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market.

Aequus Signs Exclusive Distribution Agreement with SCOPE Ophthalmics for Canadian Distribution Rights of Dry Eye Products

Retrieved on: 
Wednesday, July 6, 2022
SCOPE, SEDAR, Exocrine gland, OTCQB, Acquisition, Patient, CEO, MGD, Legislation, GLOBE, Ophthalmology, Marketing, Eye, Company, Duane syndrome, CCO, Risk, Licensed production, Perception, Technology, Macular degeneration, AMD, AQS, Forward-looking statement, Pharmaceutical industry, Risk management, Blepharitis

Under the distribution agreement, Aequus will receive the Canadian commercial rights to 10 unique products of SCOPEs portfolio of over-the-counter ophthalmology products including the OPTASE range of preservative free dry eye products.

Key Points: 
  • Under the distribution agreement, Aequus will receive the Canadian commercial rights to 10 unique products of SCOPEs portfolio of over-the-counter ophthalmology products including the OPTASE range of preservative free dry eye products.
  • We are excited to add SCOPEs unique products and brands to our existing portfolio of high-quality dry eye products.
  • These products bring many synergies and advantages to both our Canadian Eye Care professionals and their patients, said Grant Larsen, CCO of Aequus.
  • Under the proposed terms of the agreement, SCOPE will supply the products while Aequus will be responsible for Canadian authorization, marketing, distribution, and sales activities.

ModMed® Launches Resource Center to Help Medical Practices With Staff Retention

Retrieved on: 
Wednesday, July 6, 2022
Other Health, Software, Managed Care, Networks, General Health, Data Management, Technology, Hospitals, Health Technology, Practice Management, Other Technology, Health, Consensus, Efficiency, Dermatology, Gastroenterology, Patient, LinkedIn, Elective surgery, Workforce, Blog, Ophthalmology, COVID-19, Industry, National Association Medical Staff Services, Health information management, Pain management, Health, Otorhinolaryngology, EHR, Technology, Allergy, Learning, Consensus decision-making, Software, OBGYN, Soliński, RCM, Solution, Podiatry, Instagram, Practice management, Twitter, Physician, Multimedia, Medicine, Management, Medical device, Animal, Facebook

View the full release here: https://www.businesswire.com/news/home/20220706005681/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220706005681/en/
    ModMed Launches Resource Center to Help Medical Practices With Staff Retention (Photo: Business Wire)
    In response to this, healthcare technology leader ModMed has launched a comprehensive resource center, Rethinking Your Staffing Strategy , aimed at helping physicians and practice managers retain their essential staff.
  • We were not content staying on the sidelines with the large volume of healthcare leaders reporting recruitment challenges, said Dr. John Guiliana, medical director at ModMed.
  • Our resource center offers novel strategies that can help healthcare practices thrive during this challenging time.
  • We aim to continue innovating our software so that it can help reduce burnout and retain staff at healthcare practices.

Zacks Places Share Value of ABVC BioPharma at $9.50

Retrieved on: 
Wednesday, July 6, 2022
Cedars-Sinai Medical Center, FDA, ADHD, Patient, Adult, University of California, San Francisco, Trial of the century, GLOBE, Ophthalmology, Growth, CNS, Sale, Company, San Francisco, Phase, U.S. Securities and Exchange Commission, Forward-looking statement, Technology, Zacks, University, CA, Visual acuity, SEC, Risk, Incidence, NASDAQ, Safety, Stanford University, Security (finance), Pharmaceutical industry, Risk management

If and when ABVCs assets are commercialized, we estimate rapid growth for both commencing in approximately 2023 2024.

Key Points: 
  • If and when ABVCs assets are commercialized, we estimate rapid growth for both commencing in approximately 2023 2024.
  • ABVC is currently conducting a Phase II clinical study that is expected to demonstrate the safety and effectiveness of Vitargus when compared to the commonly used SF6 Gas OE.
  • ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Soak up the sun responsibly: The Canadian Ophthalmological Society reminds Canadians to protect their eyes this UV Safety Awareness Month

Retrieved on: 
Wednesday, July 6, 2022
Diagnosis, Continuing medical education, Cataract, Canadian Medical Association, Surgeon, CMA, Eye disease, Life, COS, American Ophthalmological Society, Probability, Severe cognitive impairment, Leger, Ophthalmology, Professional development, Association, Ageing, Risk, Iris, UV, RCPSC, Royal College of Physicians and Surgeons of Canada, GLARE, Eye, Canadian Association of Optometrists, Physician, Cornea, Slit lamp, Health policy, Time, Royal college, Government, CPD, Health insurance, Personal protective equipment, Telescopic sight, Veterinary medicine

"It's important to protect our eyes from harmful UV rays all year long to decrease the risk of developing cataracts later in life," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.

Key Points: 
  • "It's important to protect our eyes from harmful UV rays all year long to decrease the risk of developing cataracts later in life," says Dr. Phil Hooper, President of the Canadian Ophthalmological Society.
  • The survey also revealed that younger Canadians may not be taking enough precaution in protecting their eyes from harmful UV rays.
  • An online survey of 2003 Canadians aged 18+ was completed between June 10th and June 21st, 2022, using Leger's online panel.
  • The Canadian Ophthalmological Society (COS) is the national, recognized authority on eye and vision care in Canada.

Dr. Nancy Holekamp of the Pepose Vision Institute joins Vial as an Advisor to their Ophthalmology CRO

Retrieved on: 
Tuesday, July 5, 2022
Medical degree, Disease, Visual Science, Research, Ophthalmic, Retina, SAB, Volkmann's contracture, CRO, SAN, Traction, CTMS, Technology, George Washington University School of Medicine & Health Sciences, Vial, Gastroenterology, Washington University School of Law, Pi, Multimedia, Diabetic retinopathy, Fine chemical, Ophthalmology, Dermatology

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .

Key Points: 
  • SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .
  • Vial is pleased to announce that Dr. Nancy Holekamp of the Pepose Vision Institute was brought on as an advisor.
  • Dr. Holekamp currently serves as the Director of Retina Services at the Pepose Vision Institute in St. Louis, MO.
  • Vial has executed on that vision by launching a next-generation CRO (live in Dermatology CRO , with slated launches in Ophthalmology CRO , Oncology CRO , Gastroenterology CRO ), a site network ( Dermatology Clinical Trials , Ophthalmology Clinical Trials , Gastroenterology Clinical Trials , Women's Health Clinical Trials , Neurology Clinical Trials ), and technology platform ( VialConnect CTMS ) to accelerate research.

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss

Retrieved on: 
Tuesday, July 5, 2022
Efficiency, University, Nature Genetics, Patient, Modality, Severity, Research, Senior, Therapy, Ophthalmology, Hearing, AAV, TSE, Advertising, Company, Hearing loss, Industry, Sensorineural hearing loss, Global Burden of Disease Study, Cell Systems, CSO, Differentiable function, Lancet, Factor X, Regenerative medicine, Disease, Degenerative disease, Ear, Disability, Prevalence, RNA, Quality of life, OBE, VP, Technology, Gene, Glossary, Maintenance, Biology, Knowledge, Hope, Multimedia, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Medical device, Astellas Pharma

An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.

Key Points: 
  • An estimated 1.57 billion people globally suffer from hearing loss1, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear2.
  • This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.
  • Combined with Astellas' capabilities for gene therapy and research of sensorineural, this providesa clear path for the development of a novel in vivo reprogramming therapy forsensorineural hearing loss."
  • Through this collaboration,we will seek to address a significant unmet need in sensorineural hearing loss.